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Vancomycin‑resistant Staphylococcus aureus (VRSA), Vancomycin‑intermediate S. aureus (ViSA) and 
heterogeneous ViSA (hViSA) are subject to vancomycin treatment failure. the aim of the present 
study was to determine their precise prevalence and investigate prevalence variability depending on 
different years and locations. Several international databases including Medline (PubMed), Embase 
and Web of Sciences were searched (data from 1997 to 2019) to identify studies that addressed the 
prevalence of VRSA, ViSA and hViSA among human clinical isolates around the world. Subgroup 
analyses and meta‑regression were conducted to indicate potential source of variation. publication 
bias was assessed using egger’s test. Statistical analyses were conducted using StAtA software 
(version 14.0). Data analysis showed that VRSA, VISA and hVISA isolates were reported in 23, 50 and 
82 studies, with an overall prevalence of 1.5% among 5855 S. aureus isolates, 1.7% among 22,277 
strains and 4.6% among 47,721 strains, respectively. The overall prevalence of VRSA, VISA, and hVISA 
before 2010 was 1.2%, 1.2%, and 4%, respectively, while their prevalence after this year has reached 
2.4%, 4.3%, and 5.3%. The results of this study showed that the frequency of VRSA, VISA and hVISA 
after 2010 represent a 2.0, 3.6 and 1.3-fold increase over prior years. In a subgroup analysis of different 
strain origins, the highest frequency of VRSA (3.6%) and hVISA (5.2%) was encountered in the USA 
while VISA (2.1%) was more prevalent in Asia. Meta-regression analysis showed significant increasing 
of ViSA prevalence in recent years (p value ≤ 0.05). Based on the results of case reports (which were 
not included in the calculations mentioned above), the numbers of VRSA, ViSA and hViSA isolates 
were 12, 24 and 14, respectively, among different continents. Since the prevalence of VRSA, VISA and 
hViSA has been increasing in recent years (especially in the Asian and American continents), rigorous 
monitoring of vancomycin treatment, it’s the therapeutic response and the definition of appropriate 
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control guidelines depending on geographical regions is highly recommended and essential to prevent 
the further spread of vancomycin‑resistant S. aureus.
Staphylococcus aureus is a common pathogen that causes various community and hospital-acquired diseases, 
including endocarditis, wound abscesses, osteomyelitis, skin and soft tissue infections, pneumonia and toxin-
mediated syndromes in both healthy people and those with underlying  illnesses1,2. Over the past 20 years, this 
bacterial species has developed resistance to many antibiotics, beta-lactams in  particular3,4. During the seventies 
of the previous century, reports indicated that in the USA there was a significant increase in the morbidity and 
health care-associated costs, caused by methicillin-resistant S. aureus (MRSA)4. Currently, MRSA is endemic in 
hospitals around the world and the emergence of community-associated (CA) MRSA has added another serious 
 concern5. Vancomycin, the first glycopeptide antibiotic to be discovered, provides one of the empiric therapies 
and still is a mainstay for treatment of MRSA  infections2. In 1997, the first Vancomycin Intermediate S. aureus 
(VISA) with Minimum Inhibitory Concentration (MIC) of 8 μg/ml, was reported from  Japan6. In 2002, the 
first case of Vancomycin-resistant S. aureus (VRSA) was reported in a diabetic patient in the  USA7. Previously, 
in vitro studies suggested the existence of various mechanisms for vancomycin resistance in MRSA, the main one 
being the decreased permeability and the increased thickness of the cell wall and hence a decreased availability 
of vancomycin for intracellular target molecules. Another type of resistance was caused by plasmid-mediated 
vancomycin resistance genes (vanA, vanB, vanD, vanE, vanF, and vanG) which may have been transferred 
from enterococcal  species6,8–10. Besides, a recent study has shown that VISA growth rate is lower and that the 
cells harbor a thicker cell wall than those fully susceptible.9,11. Heterogeneous VISA (hVISA) show MICs in 
the susceptible range (≤ 2 μg/mL), but they contain a sub-population that expresses a resistant  phenotype12,13. 
Infections caused by VISA and hVISA lead to higher rates of vancomycin treatment failure and are associated 
with extended hospitalization, higher risk of persistent infection, and elevated treatment  costs13,14. Despite a 
published systematic review and meta-analysis study on the prevalence VISA and  hVISA15 5 years ago, there 
has not been published a comprehensive study on the prevalence VRSA, VISA and hVISA worldwide, yet. In 
the present systematic review and meta-analysis, we pooled published studies that reported the prevalence of 
VRSA, VISA and hVISA. The findings of the current study will more precisely define the current epidemiology 
of VRSA, VISA and hVISA and may help to develop more appropriate antibiotic stewardship policies to combat 
vancomycin resistance.
Methods
Search strategy. A comprehensive systematic literature search was performed in Medline (via PubMed), 
Embase, and Web of Science databases for original research articles published from 1997 until September 2019. 
The following terms were applied in our search strategy: Staphylococcus aureus, S. aureus, Vancomycin Resistant 
Staphylococcus aureus, Vancomycin Resistant S. aureus, VRSA, Vancomycin Intermediate Staphylococcus aureus, 
Vancomycin Intermediate S. aureus, VISA, heterogeneous Vancomycin Intermediate Staphylococcus aureus, het-
erogeneous Vancomycin Intermediate S. aureus and hVISA. We also searched the bibliographies of relevant 
articles to identify additional studies.
inclusion and exclusion criteria. All original human studies on the prevalence of VRSA, VISA and 
hVISA among clinical S. aureus isolates that reported sufficient data (including prevalence, evaluation meth-
ods, and country of origin) were  assessed5,12,13,16–197. Titles, abstracts and full texts of the recorded studies were 
checked based on the inclusion and exclusion criteria. The exclusion criteria were: (1) animal research only, (2) 
studies considering vancomycin-resistant bacteria beyond S. aureus, (3) reviews, (4) abstracts presented in con-
ferences, and (5) duplicate studies. Two of the authors (AS and MT) evaluated all studies based on inclusion and 
exclusion criteria and selected the appropriate papers.
Data extraction and definitions. The following items were extracted from each included study: the last 
name of the first author, study years, time of publication, country, number of VRSA, VISA and hVISA, number 
of patients with staphylococcal infection, phenotypic methods used, genotypic identification methods applied 
and the sample source. Data were collected by two independent examiners and verified by another researcher. 
According to the CLSI, the definition of VRSA, VISA and hVISA in S. aureus isolates with reduced susceptibil-
ity to vancomycin is MIC ≥ 16 μg/mL, MIC of 4–8 μg/mL; and MIC of 1–2 μg/mL, respectively. Furthermore, 
articles before 2006 used the old definition of VRSA and VISA (VRSA, MIC ≥ 32 μg/mL; VISA, MIC of 8–16 μg/
mL)198.
Quality assessment. All reviewed articles were evaluated for quality (according to guidelines developed by 
the Joanna Briggs Institute), and only high-quality articles that met those rules were  included199.
Meta‑analysis. Statistical analysis was conducted with STATA software, version 14.0 (Stata Corporation, 
College Station, Texas, USA) to report the global prevalence of VRSA, VISA and hVISA isolated from human 
clinical samples. The data were pooled using the fixed-effects (FEM)200 and the random-effects model (REM). 
Subgroup analyses were conducted based on the type of isolates, publication year and geographic areas (con-
tinent/countries). Statistical heterogeneity was evaluated using the Q-test and the I2 statistical  methods201. P 
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Meta‑regression analysis. We evaluated whether the prevalence of VRSA, VISA and hVISA changed over 
time by performing restricted maximum likelihood (REML) random effect meta-regression analysis based on 
publication year as the moderator. A p value less than 0.05 (p value ≤ 0.05) was considered statistically significant.
Results
characteristics of included studies. In total, 3200 citations were recorded in the initial database searches. 
Since we collected data from three databases, many duplicate studies were included. After removing 975 dupli-
cates, titles and abstracts of 2225 articles were checked and 1418 irrelevant studies not meeting the Briggs Insti-
tute rules were excluded from our review. In the next screening, 477 non-relevant studies were removed upon 
reading the full text. In the end, 155 articles were included in the final analysis (Fig. 1 shows a flow chart).
the prevalence of VRSA, ViSA and hViSA isolates among human clinical isolates. Out of 155 
articles that reported the prevalence of VRSA, VISA and hVISA, 89 studies were from Asia, 22 from Europe, 31 
from America, 9 from Africa and 4 from Oceania (Table 1). Data analysis showed that VRSA, VISA and hVISA 
isolates were reported in 23, 50 and 82 studies, with an overall prevalence of 1.5% [(95% CI) 1.0–2.0] among 
5855 S. aureus isolates, 1.7% [(95% CI) 1.3–2.0] among 22,277 strains and 4.6% [(95% CI) 4.1–5.1] among 
47,721 strains, respectively (Table 2).
Figure 1.  Flow chart of publication selection and their inclusion in the systematic review.
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Subgroup Isolates Country Prevalence% (95% CI) Number of studies P value I-squared Tau-squared
Asia
VRSA
Overall 1.3 (0.8–1.9) 18 0.000 63.7 P < 0.001
Iran 1.3 (0.5–2.0) 10 0.007 60.2 P < 0.001
India 1.6 (0.3–2.8) 5 0.008 70.9 P < 0.001
Bangladesh 4.5 (0.0–10.7) 1 0.727 0.0 P < 0.001
Pakistan 3.3 (0.5–6.2) 1 0.727 0.0 P  < 0.001
Jordan 4.0 (0.6–7.4) 1 0.023 0.0 P  < 0.001
VISA
Overall 2.1 (1.6–2.6) 28 0.000 88.3% P < 0.001
China 0.5 (0.1–1.0) 2 0.960 0.0 P < 0.001
India 4.6 (1.9–7.2) 6 0.000 88.3 P < 0.001
Iran 3.6 (1.4–5.7) 6 0.000 77.7 P  < 0.001
Japan 0.6 (0.0–1.3) 3 0.074 61.6 P  < 0.001
Korea 0.7 (0.1–1.3) 2 0.626 0.0 P  < 0.001
Pakistan 5.6 (1.9–9.2) 3 0.000 87.6 P  < 0.001
Saudi-Arabia 18.0 (11.9–24.1) 1 – – P  < 0.001
Singapore 12.5 (3.8–21.2) 1 – – P  < 0.001
Taiwan 1.9 (0.0–4.0) 3 0.000 95.7 P  < 0.001
Thailand 0.3 (0.0–0.7) 1 – – P < 0.001
hVISA
Overall 4.7 (3.9–5.4) 43 0.000 92.6% P < 0.001
China 10.0 (5.5.14.4) 6 0.000 90.9 P < 0.001
Singapore 3.0 (0.2–5.8) 2 0.370 0.0 P < 0.001
Taiwan 1.5 (0.4–2.6) 5 0.001 78.9 P < 0.001
Thailand 9.7 (9.6–15.7) 5 0.000 96.2 P < 0.001
Japan 8.4 (5.3–11.4) 5 0.001 79.9 P < 0.001
Korea 3.3 (2.1–4.5) 8 0.000 91.4 P < 0.001
Lebanon 4.4 (0.6–8.2) 1 – – P < 0.001
India 2.5 (0.5–5.0) 4 0.006 76.2 P < 0.001
Malaysia 2.5 (1.0–4.0) 3 0.594 0.0 P < 0.001
Philippines 3.6 (0.0–10.4) 1 – – P < 0.001
Vietnam 4.4 (0.0–8.8) 2 0.235 29.1 P < 0.001
Israel 6.1 (3.2–8.9) 1 – – P < 0.001
Europe
VRSA
Overall 1.1 (0.0–2.7) 1 – – P < 0.001
Italy 1.1 (0.0–2.7) 1 – – P < 0.001
VISA
Overall 1.8 (0.8–2.8) 6 0.027 60.5% P < 0.001
Belgium 2.5 (1.1–4.0) 1 – – P < 0.001
France 2.2 (0.5–3.8) 2 0.87 65.8 P < 0.001
Turkey 2.7 (0.0–6.5) 1 – – P < 0.001
Germany 0.7 (0.0–1.6) 1 – – P < 0.001
Italy 1.4 (0.0–3.2) 1 – – P < 0.001
hVISA
Overall 4.4 (3.2–5.5) 15 0.000 97.4% P < 0.001
France 5.9 (0.0–16) 2 0.000 99.5 P < 0.001
Belgium 0.2 (0.1–0.4) 3 0.479 0.0 P < 0.001
Ireland 2.5 (1.9–3.0) 1 – – P < 0.001
Italy 6.9 (2.5–11.3) 4 0.000 85.4 P < 0.001
Poland 4.9 (0.7–9.0) 1 – – P < 0.001
Turkey 11.4 (1.7–21.1) 3 0.000 93.4 P < 0.001
UK 3.4 (2.7–4.1) 1 – – P < 0.001
America
VRSA
Overall 3.6 (0.5–6.6) 1 – – P < 0.001
Brazil 3.6 (0.5–6.6) 1 – – P < 0.001
VISA
Overall 1.0 (0.5–1.4) 9 0.023 55.0% P < 0.001
USA 0.9 (0.5–1.3) 7 0.054 51.5 P < 0.001
Brazil 4.1 (1.0–7.3) 2 0.352 0.0 P < 0.001
hVISA
Overall 5.2 (4.3–6.1) 21 0.000 96.1% P < 0.001
USA 4.7 (3.7–5.6) 16 0.000 96.6 P < 0.001
Brazil 17.3 (3.9–30.7) 3 0.000 88.4 P < 0.001
Canada 5.3 (3.3–7.3) 1 – – P < 0.001
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the prevalence of VRSA, ViSA and hViSA in two study periods. To analyze the trends for changes 
in the prevalence of VRSA, VISA and hVISA in more recent years, we performed a subgroup analysis for two 
periods (before 2010 and 2010–2019) (Table 2, Fig. 2). The prevalence of VRSA, VISA and hVISA gradually 
increased. Before 2010, the prevalence was 1.2% (95% CI 0.5–1.8) among 2444 S. aureus isolates, 1.2% (95% 
CI 0.9–1.5) among 18,469 isolates and 4.0 (95% CI 2.9–5.0) among 41,190 S. aureus, respectively. Prevalence 
reached 2.4% (95% CI 1.4–3.5) among 3411 S. aureus isolates, 4.3% (95% CI 3.0–5.7) among 3808 isolates and 
5.3% (95% CI 1.8–4.1) among 6531 isolates in 2010–2019, respectively. The changes in VRSA, VISA and hVISA 
prevalence between periods are presented in Table 2. The results of this review indicate that the frequency of 
VRSA, VISA and hVISA after 2010 represent a 2.0, 3.6 and 1.3-fold increase over the prior years (Fig. 2).
The prevalence of VRSA, VISA and hVISA on different continents. The prevalence of VRSA was 
1.2% (95% CI 0.7–1.8) among 5043 S. aureus isolates in Asia, 1.1% (95% CI 0.0–2.7) among 179 isolates in 
Europe, 3.6% (95% CI 0.5–6.6) among 140 isolates in America and 2.5% (95% CI 0.1–4.8) among 493 isolates 
in Africa. There has been no report of VRSA from Oceania (Figs. 3, 4, 5, 6). The results of this review showed 
that the prevalence of VISA isolates was 2.1% (95% CI 1.6–2.6) among 13,449 S. aureus isolates, 1.8% (95% 
CI 0.8–2.8) among 2198 isolates, 1.0% (95% CI 0.5–1.4) among 5040 isolates, 1.8% (95% CI 0.1–3.4) among 
1072 isolates and 0.6% (95% CI 0.0–1.3) among 518 isolates from Asia, Europe, America, Africa and Oceania, 
respectively (Figs. 3, 4, 5, 6). Moreover, the prevalence of hVISA in Asia, Europe, America, Africa and Oceania 
were 4.7% (95% CI 3.9–5.4) among 16,955 S. aureus isolates, 4.4% (95% CI 3.2–5.5) among 14,680 isolates, 5.2% 
(95% CI 4.3–6.1) among 15,532 isolates, 4.0% (95% CI 0.2–7.8) among 100 isolates and 11.2% (95% CI 8.3–14.1) 
among 454 isolates, respectively (Figs. 3, 4, 5, 6).
Table 1.  Prevalence of VRSA, VISA and hVISA isolated from human clinical samples in different continents/
countries based on published original studies. Tau-squared: the extent of variation among the effects observed 
in different studies; I-squared: the percentage of variance in a meta-analysis that shows study heterogeneity.
Subgroup Isolates Country Prevalence% (95% CI) Number of studies P value I-squared Tau-squared
Africa
VRSA
Overall 2.5 (0.1–4.8) 3 0.061 64.2 P < 0.001
Algeria 1.4 (0.0–2.9) 1 – – P < 0.001
Egypt 5.5 (2.3–8.7) 1 – – P < 0.001
Nigeria 1.4 (0.0–4.0) 1 – – P < 0.001
VISA
Overall 1.8 (0.1–3.4) 5 0.003 75.0% P < 0.001
Algeria 0.6 (0.1–1.1) 3 0.761 0.0 P < 0.001
Kenya 4.2 (0.6–7.9) 1 – – P < 0.001
Nigeria 15.1 (6.9–23.3) 1 – – P < 0.001
hVISA
Overall 4.0 (0.2–7.8) 1 – – P < 0.001
Egypt 4.0 (0.2–7.8) 1 – – P < 0.001
Oceania
VRSA NR NR – – – P < 0.001
VISA
Overall 0.7 (0.0–1.3) 2 0.332 0.0% P < 0.001
Australia 0.7 (0.0–1.3) 2 0.332 0.0 P < 0.001
hVISA
Overall 11.2 (8.3–14.1) 2 0.637 0.0 P < 0.001
Australia 11.2 (8.3–14.1) 2 0.637 0.0 P < 0.001
Table 2.  Prevalence of VRSA, VISA and hVISA isolated from human clinical samples based on two study 
periods.
Subgroup Isolates Prevalence% (95% CI) Number of studies P value I-squared (%) Tau-squared
Overall
VRSA 1.5 (1.0–2.0) 23 0.000 65.3 0.0001
VISA 1.7 (1.3–2.0) 50 0.000 83. 0.0001
hVISA 4.6 (4.1–5.1) 82 0.000 89.2 0.0003
Research before 2010
VRSA 1.2 (0.5–1.8) 8 0.017 59.0 0.0000
VISA 1.2 (0.9–1.5) 31 0.000 79.0 0.0000
hVISA 4.0 (2.9–5.0) 70 0.000 84.8 0.0003
Research after 2010
VRSA 2.4 (1.4–3.5) 15 0.000 69.0 0.0002
VISA 4.3 (3.0–5.7) 19 0.000 86.3 0.0005
hVISA 5.3 (2.5–8.3) 12 0.000 84.3 0.0003
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The prevalence of VRSA, VISA and hVISA on different continents based on case report‑
ing. After the meta-analysis of the prevalence of VRSA, VISA and hVISA among human clinical isolates in 
different continents, we evaluated the frequency of these three types of S. aureus isolates based on case reports 
published in the mentioned electronic databases. Based on the results of case reports (Supplementry informa-
tion Table S2) (which were not taken into account during the analyses already mentioned above), the numbers 
of VRSA, VISA and hVISA isolates were 12, 24 and 14 among different continents. However, most reports have 
been from Asia and America continents. There has been no report of VRSA isolates in Europe and Oceania. 
Oceania was the only continent from which there were no case reports on VISA (Figs. 7 and 8).
Meta‑regression analysis. The results of meta-regression showed that the prevalence of VISA was signifi-
cantly increase by increasing published year (p value < 0.05, Supplementry information figure S1). The results 









Percentage of VRSA, VISA and hVISA during two periods
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Figure 2.  Distribution of VRSA, VISA and hVISA isolates among different continents based on published 
original and case report studies.
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increased, but this increase was statistically non-significant (p value > 0.05; Table 3 and Supplementry informa-
tion Figure S1).
Discussion
Frequent use of vancomycin as the drug of choice for treatment of infections caused by multidrug-resistant MRSA 
has putatively led to selection of the is isolates with reduced susceptibility to  vancomycin15,203. In this study we 
report the prevalence of VRSA, VISA and hVISA around the world. The global prevalence of VRSA, VISA and 
hVISA isolates was 1.5%, 1.7%, and 4.6%, respectively.













Percentage of VRSA, VISA and hVISA among different 








Scientific RepoRtS |        (2020) 10:12689  | https://doi.org/10.1038/s41598-020-69058-z
www.nature.com/scientificreports/
In studies mentioned in Supplementry information Table S1, presence of vanA in VRSA strains by PCR 
showed that 69% (55/79) of the VRSA strains were vanA positive. This elevated rate of vanA in these bacteria 
indicates that the resistance determinant was possibly acquired from a vancomycin-resistant Enterococcus  spe-
cies or from one of the other vanA positive organisms living in the human gastro-intestinal tract. Absence of 
vanA in the other isolates suggests that cell wall thickening and possibly vancomycin affinity trapping may be 
responsible for the development of vancomycin resistance in these  isolates19. Furthermore, many studies reported 
a failure to detect the vanB gene.
Regarding VISA and hVISA strains, although, there is no clear overall genetic explanation for these 
 phenotypes15, the main mechanisms of reduced susceptibility to vancomycin among VISA strains are mutations 
in cell wall-associated genes (thickened cell wall with an increased number of peptidoglycan layers)204,205, and/
or in the ribosomal gene rpoB203. The prolonged usage of vancomycin can lead to changes in cell wall pattern-
ing or reduced expression of penicillin-binding proteins. This may accumulate from heterogeneous to selected 
homogeneous VISA-type  resistance203,206. Noteworthy, when the cell wall gets thicker, the vancomycin MIC level 
 increases207,208. Because of enhanced selective pressure, evolution of hVISA/VISA strains is more rapid in the 
hospital setting than in the community and therefore VISA is considered a more significant clinical problem than 
 VRSA209. Furthermore, the results of meta-regression results showed the prevalence of the VISA was significantly 
increase over the time compare to the VRSA and hVISA. It seems that the real incidence of hVISA/ VISA strains 
is much higher than the present reports and hence there is a clear need for the development of new diagnostic 
methods for detecting hVISA/VISA. This also includes the development for new antimicrobial susceptibility 
tests (AST). For instance, in several studies, the PAP-AUC gold standard AST method was not used due to its 
time-consumption and technical difficulty. Other methods such as Disk Diffusion testing are unable to detect 
and distinguish these  strains9. In overall, all studies used the culture-based methods such as E-test, PAP-AUC, 
broth dilution, and agar dilution. Moreover, some studies beside the culture-based methods, used PCR for 
detection of resistant-related gene. Since global scale sort of the same type and frequency of methods was used, 
the differences between developed and developing countries cannot be hypothetically addressed towards the 
use of different AST systems.
VRSA and/or VISA with resistance to multiple other antibiotics, including β-lactams, have been isolated from 
livestock animals that highlights the abuse of antibiotic in that sector and the suspected use of antibiotics as a 
food  supplement210,211. The potential reasons for the emergence or detecting more resistant strains during recent 
years include: more frequent use of vancomycin for treatment of MRSA infections, better use of diagnostics, 
Asia Europe America Africa Oceania
VRSA 65 2 5 15 0
VISA 295 50 52 22 4


















The number of VRSA, VISA and hVISA isolates among 
different continents based on published original studies
Figure 6.  Prevalence of VRSA, VISA and hVISA isolated from human clinical samples based on two study 
periods.
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inadequate surveillance for drug-resistant strains and a possible change in the vancomycin-resistance breakpoints 
since  2006212,213.
The prevalence of VRSA in Asia, Europe, America and Africa was 1.2%, 1.1%, 3.6% and 2.5%, respectively. 
By the way, 65 strains of VRSA were found in Asia versus only 5 VRSA in America. The prevalence of VISA in 
Asia was higher than on the other continents. It should be noted that 67% (327/485) of vancomycin-resistant 
strains were reported from Iran and India. Therefore, our data shows that the Asian data are biased towards two 
countries but also that the emergence of VRSA in India and Iran warrants active microbiological surveillance 
and careful monitoring of vancomycin therapy. There are several factors involved in the higher number of VRSA 
and a higher prevalence of VISA in Asia, in comparison to Europe/America countries. Most of the Asian coun-
tries are developing countries with lower public hygiene standards and different attitudes towards antimicrobial 
treatments. Furthermore, population density can lead to more MRSA infections through enhanced microbial 
transmission. Higher vancomycin use for the treatment of infections can play a role as  well15.
Previous studies have helped to identify risk factors that may contribute to VISA emergence such as previ-
ous MRSA colonization, hemodialysis dependence, long-term use of vancomycin, hospitalization in ICU and 
use of indwelling devices. There is no clarity on the precise clinical consequences of vancomycin non-suscepti-
bility among S. aureus strains. Although some meta-analyses have addressed the association between elevated 
vancomycin MICs and worse clinical  outcomes214,215, a recent prospective cohort study suggested exactly the 
 opposite216. Previous studies have also demonstrated a correlation between increased vancomycin MICs and 
daptomycin resistance in VISA  isolates217,218. Furthermore, decreased vancomycin susceptibility is associated 
with increased susceptibility to beta-lactams. Therefore, the combination of vancomycin and beta-lactams can be 
a good option for treatment of hVISA or VISA  infections198,219. On the other hand, those correlated resistances 
Figure 8.  Number of VRSA, VISA and hVISA isolates in different continent based on published original and 
case report studies. OA original article, CR case report.
Table 3.  Meta regression analysis of published year in prevalence VRSA, VISA and hVISA isolates among 
human clinical samples.
Moderator Type of isolate No studies Coefficient Standard error Z value P value
Published year
VRSA 23 0.03822 0.02051 1.86318 0.062
VISA 50 0.10495 0.08376 9.70814 0.000
hVISA 82 − 0.00016 0.00667 − 0.02334 0.981
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can lead to problems in elucidating the role of the individual resistance marker in disease severity. Since there is 
an emerging and increasing rate of resistance to vancomycin, thorough monitoring of the success of vancomycin 
treatment is essential.220. The majority of VRSA strains belonged to same clonal complex (CC) such as CC5 in 
the USA. Interestingly, there is high prevalence of the CC5 in healthcare settings. Unlike VRSA, hVISA/VISA 
has been associated with many clones such as CC5, CC8, CC30, and  CC45221.
Antibiotics such as trimethoprim-sulfamethoxazole, tetracyclines, fluoroquinolones, and clindamycin are 
alternative treatment choices for community-acquired MRSA infections. New drugs such as linezolid, daptomy-
cin, tigecycline, and sodium fusidate are suggested for isolates with a vancomycin MIC of greater than 2 μg/mL198. 
Finally, in order to control the spread of vancomycin resistant staphylococci, contact precautions, disinfection of 
care equipment and the environment, plus adequate antimicrobial stewardship are highly  recommended222–224.
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